False-Positive Findings on Dopamine Transporter SPECT Due to Therapeutic Dextroamphetamine and Amphetamine
False-Positive Findings on Dopamine Transporter SPECT Due to Therapeutic Dextroamphetamine and Amphetamine
复制标题
由于治疗性右旋苯丙胺和苯丙胺导致多巴胺转运蛋白 SPECT 出现假阳性结果
DOI：
10.2967/jnmt.117.201558
复制
发表时间：
2017
期刊：
影响因子：
--
通讯作者：
P. Kuo
中科院分区：
文献类型：
--
作者：
J. Frankl;Sudeshna Bose;P. Kuo
多巴胺转运蛋白SPECT是一个准确的辅助诊断帕金森病的临床评价时，是困难的。多巴胺能药物可能会显着影响多巴胺转运蛋白的可用性，因此，摄取多巴胺转运蛋白示踪剂。一名患者在服用安非他明和安非他明治疗注意力缺陷多动障碍时出现了假阳性多巴胺转运蛋白SPECT结果。安非他明治疗后SPECT结果正常化被扣留。准确的用药史结合干扰多巴胺转运蛋白成像的药物知识对于确保准确性至关重要。
Dopamine transporter SPECT is an accurate adjunct to clinical evaluation for Parkinson disease when the diagnosis is difficult. Dopaminergic medications may significantly affect dopamine transporter availability and, thus, uptake of dopamine transporter tracers. A patient had a false-positive dopamine transporter SPECT result while she was taking dextroamphetamine and amphetamine for attention-deficit hyperactivity disorder. The SPECT findings normalized after amphetamine therapy was withheld. An accurate medication history combined with knowledge of drugs that interfere with dopamine transporter imaging is critical to ensure accuracy.